A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Ye ZhuJames P MoriartyKristi M SwansonPaul Y TakahashiSuzette J BielinskiRichard WeinshilboumLiewei WangBijan J BorahPublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2020)
Compared with usual care, preemptive PGx panel testing was cost-effective in cardiovascular disease management.